TYPE 4A METABOTROPIC GLUTAMATE-RECEPTOR - IDENTIFICATION OF NEW POTENT AGONISTS AND DIFFERENTIATION FROM THE L-(-2-AMINO-4-PHOSPHONOBUTANOIC ACID-SENSITIVE RECEPTOR IN THE LATERAL PERFORANT PATHWAY IN RATS())
Pa. Johansen et al., TYPE 4A METABOTROPIC GLUTAMATE-RECEPTOR - IDENTIFICATION OF NEW POTENT AGONISTS AND DIFFERENTIATION FROM THE L-(-2-AMINO-4-PHOSPHONOBUTANOIC ACID-SENSITIVE RECEPTOR IN THE LATERAL PERFORANT PATHWAY IN RATS()), Molecular pharmacology, 48(1), 1995, pp. 140-149
Before the discovery of the metabotropic glutamate receptors (mGluRs),
the glutamate analogue L-2-amino-4-phosphonobutanoic acid (L-AP4) was
identified as a potent presynaptic inhibitor of evoked synaptic trans
mission in the lateral perforant pathway in rats. The localization and
L-AP4 sensitivity of the mGluR4a subtype of mGluRs were consistent wi
th the hypothesis that this receptor mediates the synaptic depressant
effects of L-AP4 in the lateral perforant pathway. In the present stud
y, the pharmacology of mGluR4a expressed in baby hamster kidney 570 ce
lls was characterized and compared with that previously reported for t
he lateral perforant pathway responses. The endogenous excitatory amin
o acid L-aspartate was inactive at mGluR4a, whereas L-homocysteic acid
was only 5-fold less potent than L-glutamate. These data suggest that
L-homocysteic acid may be an endogenous agonist at mGluR4a. Of the 30
L-AP4 analogues examined, several compounds were identified as agonis
ts at mGluR4a. The cyclopropyl-AP4 analogue (Z)-(+/-)-2-amino-2,3-meth
ano-4-phosphonobutanoic acid inhibited forskolin-stimulated cAMP produ
ction with an EC(50) of 0.58 mu M, which is comparable to that of L-AP
4 (EC(50) = 0.43 mu M). Two other cyclic analogues of L-AP4 were appro
ximately 10-fold less potent as agonists at mGluR4a, i.e., -amino-3-(p
hosphonomethylene)cyclobutanecarboxylic acid (EC(50) = 4.4 mu M) and (
E)-(+/-)-2-amino-2,3-methano-4-phosphonobutanoic acid (EC(50) = 7.9 mu
M). Comparison of the potencies of the compounds for activation of mG
luR4a with their potencies for inhibition of lateral perforant pathway
responses demonstrates that some compounds have comparable activities
in the two systems, whereas several compounds are at least 10-fold mo
re potent in one of the systems. In addition, although the mGluR antag
onist (+)-alpha-methyl-4-carboxyphenylglycine blocked the effects of L
-AP4 in the lateral perforant pathway, it did not block the effects of
L-AP4 at the cloned receptor. These data provide evidence that mGluR4
a does not mediate the effects of L-AP4 in the lateral perforant pathw
ay, they provide new tools to identify the function of these receptors
in the mammalian central nervous system, and they indicate that the e
ffects of L-AP4 in the lateral perforant pathway are mediated by a (+)
-alpha-methyl-4-carboxyphenylglycine-sensitive receptor.